Aopu Mai: Issuance of shares to purchase 100% equity of Pengli Biology, completion of transfer of the target assets.

Aoupumai announced that the company plans to acquire 100% equity of Pengli Bio by issuing shares and paying cash, and to raise matching funds. On January 14, 2026, the equity of Pengli Bio was transferred, and the company directly held 374,808,585 shares, with a shareholding ratio of 100%. Pengli Bio became its wholly-owned subsidiary and was included in the consolidated financial statements. In the future, the company needs to complete procedures such as paying the transaction price, raising matching funds, and handling industrial and commercial changes. The intermediary agency believes that the transfer procedures of this transaction are legal and effective, and there are no substantial obstacles in handling subsequent matters.